Research programme: SAIK - Active Biotech
Alternative Names: SAIK research programme - Active BiotechLatest Information Update: 25 Nov 2003
At a glance
- Originator Active Biotech
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 25 Nov 2003 Discontinued - Preclinical for Asthma in Sweden (unspecified route)
- 25 Nov 2003 Discontinued - Preclinical for Psoriasis in Sweden (unspecified route)
- 25 Nov 2003 Discontinued - Preclinical for Rheumatoid arthritis in Sweden (unspecified route)